Last reviewed · How we verify
Bilamid (hydroxymethylnicotinamide)
Bilamid (generic name: hydroxymethylnicotinamide) is a hydroxymethylnicotinamide drug. It is currently in unknown development.
Bilamid works by modifying the activity of nicotinamide, a form of vitamin B3, to produce a therapeutic effect.
Bilamid, also known as hydroxymethylnicotinamide, is a small molecule drug of the hydroxymethylnicotinamide class. Unfortunately, there is limited information available on this compound, including its target, approved indications, and commercial status. As a result, it is difficult to provide a comprehensive summary of its use and safety profile. Further research is needed to determine the efficacy and safety of Bilamid in clinical settings. Its development and current ownership are also unclear.
At a glance
| Generic name | hydroxymethylnicotinamide |
|---|---|
| Drug class | hydroxymethylnicotinamide |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Think of it like a key that unlocks a specific process in the body. By changing the way nicotinamide works, Bilamid can help to treat certain conditions. This process is complex and involves many different molecules and cells, but essentially, Bilamid helps to regulate the way the body uses energy.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bilamid CI brief — competitive landscape report
- Bilamid updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Bilamid
What is Bilamid?
How does Bilamid work?
What is the generic name of Bilamid?
What drug class is Bilamid in?
What development phase is Bilamid in?
Related
- Drug class: All hydroxymethylnicotinamide drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing